Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

Medical Oncology

Volumn 25, Issue 3, 2008, Pages 356-359

  Dincer, Murat ^a   Altundag, Kadri ^a   Harputluoglu, Hakan ^a   Aksoy, Sercan ^a   Cengiz, Mustafa ^a   Gullu, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bone metastases; Breast cancer; Renal safety; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; PHOSPHORUS; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOCALCEMIA; KIDNEY FUNCTION; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; BONE TUMOR; BREAST TUMOR; DRUG EFFECT; KIDNEY; LONGITUDINAL STUDY; METASTASIS; MIDDLE AGED; PATHOLOGY; TIME;

ADULT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KIDNEY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TIME FACTORS;

EID: 57749174686     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9045-3     Document Type: Article

References (17)

1. K Manders LV van de Poll-Franse GJ. Creemers 2006 Clinical management of women with metastatic breast cancer: a descriptive study according to age group BMC Cancer 6 179
2. RE. Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165 76
3. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474.
4. A. Lipton 2005 Management of bone metastases in breast cancer Curr Treat Options Oncol 6 161 71
5. HM Bounameaux 1983 Renal failure associated with intravenous diphosphonates Lancet 1 471
6. N Zojer AV Keck M. Pecherstorfer 1999 Comparative tolerability of drug therapies for hypercalcaemia of malignancy Drug Saf 21 389 406
7. GS Markowitz 2003 Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 281 9
8. SM Ali FJ Esteva G. Hortobagyi 2001 Safety and efficacy of bisphosphonates beyond 24 months in cancer patients J Clin Oncol 19 3434 7
9. V Guarneri S Donati M Nicolini S Giovannelli R D'Amico PF. Conte 2005 Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years Oncologist 10 842 8
10. T Tanvetyanon PJ. Stiff 2006 Management of the adverse effects associated with intravenous bisphosphonates Ann Oncol 17 897 907
11. DW Cockcroft MH. Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41
12. JT Chang L Green J. Beitz 2003 Renal failure with the use of zoledronic acid N Engl J Med 349 1676 9 (discussion 1676-9.)
13. GS Markowitz 2001 Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate J Am Soc Nephrol 12 1164 72
14. N Gokden 2007 Potential effect of zoledronate therapy in heavy proteinuria Clin Nephrol 67 263 5
15. J. Balla 2005 The issue of renal safety of zoledronic acid from a nephrologist's point of view Oncologist 10 306 8
16. O Altundag 2004 Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis Med Hypotheses 63 1010 3
17. D Aguiar Bujanda U Bohn Sarmiento MA Cabrera Suarez J. Aguiar Morales 2007 Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis Ann Oncol 18 556 60